Dr. Tiejun Yang 杨铁军
Chief Physician
Department of Urology, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive surgery and comprehensive treatment for urinary tract tumors and benign conditions, including adrenal, kidney, ureter, bladder, prostate, testicular, and penile diseases. Focuses on complex and difficult cases.
Dr. Yang holds a doctorate in surgery and is a graduate supervisor. Trained at the University of Pittsburgh Medical Center (UPMC) in minimally invasive surgery and comprehensive treatment. Leads nine national and provincial research projects, published over 40 papers, and received seven scientific achievement awards.
Professional roles
- Chair, China Anti-Cancer Association Committee on Integrated Traditional Chinese and Western Medicine for Bladder Cancer
- Standing Committee Member, China Anti-Cancer Association Committee on Integrated Traditional Chinese and Western Medicine for Prostate Cancer
- Member, Chinese Medical Association
- Member, Chinese Society of Clinical Oncology (CSCO) Kidney Cancer Committee
Name order: in Chinese the family name comes first (Yang Tiejun). Papers usually list the name as Tiejun Yang or Yang T.
Selected publications
24 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Rep, 2025 (senior author): Diet-metabolism-transcription axis modulates the sensitivity to CDK4/6 inhibitors through RB1 in prostate cancer. PubMed 41196681
- Front Oncol, 2024 (senior author): Case report: Isolated eyelid metastasis of ccRCC 5 years after receiving radical nephrectomy. PubMed 38559565
- Front Oncol, 2023 (senior author): Clinical study of renal artery cold perfusion combined with laparoscopic nephron retention in the treatment of complex renal angiomyolipoma. PubMed 37920170
- Asian J Surg, 2023 (senior author): Penile cancer with bilateral inguinal lymph node metastases surviving for more than 4 years: A case report. PubMed 36307266
- Front Oncol, 2022 (senior author): Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma. PubMed 36620538
- BMC Surg, 2022 (senior author): A laparoscopic radical inguinal lymphadenectomy approach partly preserving great saphenous vein branches can benefit for patients with penile carcinoma. PubMed 35397549
- Front Genet, 2021 (senior author): Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer. PubMed 34512722
- Front Mol Biosci, 2021 (senior author): Identification of a Prognostic Signature Associated With the Homeobox Gene Family for Bladder Cancer. PubMed 34368227
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion